PROTEOMICS INTERNATIONAL LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 AUD | +3.81% |
|
-0.46% | +21.79% |
| 03-25 | Proteomics International Signs Agreement with University of Oxford for Endometriosis Study | MT |
| 03-19 | Proteomics Says PromarkerD's US Launch Delayed | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +21.79% | 90.89M | - | ||
| +8.64% | 105B | B+ | ||
| -0.90% | 104B | B+ | ||
| +5.44% | 22.94B | B | ||
| -12.25% | 22.34B | B+ | ||
| -6.31% | 19.25B | A- | ||
| -37.08% | 17.08B | A- | ||
| -8.69% | 16.96B | B | ||
| +7.59% | 14.16B | C+ | ||
| +38.96% | 12.63B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PIQ Stock
- Ratings Proteomics International Laboratories Limited